Your guide to the Trump drug price plan: who it affects and how

President Donald Trump’s new plan, “American Patients First,” is supposed to make U.S. drug prices cheaper.

But the proposal isn’t expected to hurt drugmakers, middlemen or any other part of the U.S. drug supply chain, at least for now. For some players, there could be long-term concerns, including for pharmacy-benefit managers and other drug system middlemen.

Many, though, had their shares surge after Trump’s speech on Friday, where he introduced the plan.

“So — was that it?” asked Raymond James analyst John Ransom. The biggest takeaway “was that there was nothing new,” Ransom said.

Read: President Trump’s big drug price speech boosts pharma stocks

>>> Original Source <<<